AC Immune SA (ACIU): Price and Financial Metrics


AC Immune SA (ACIU): $2.52

-0.03 (-1.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACIU Stock Price Chart Interactive Chart >

Price chart for ACIU

ACIU Price/Volume Stats

Current price $2.52 52-week high $5.40
Prev. close $2.55 52-week low $2.06
Day low $2.38 Volume 77,000
Day high $2.64 Avg. volume 88,196
50-day MA $2.83 Dividend yield N/A
200-day MA $3.30 Market Cap 210.55M

AC Immune SA (ACIU) Company Bio


AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by mis-folding proteins. The company was founded in 2003 and is based in Lausanne, Switzerland.


ACIU Latest News Stream


Event/Time News Detail
Loading, please wait...

ACIU Latest Social Stream


Loading social stream, please wait...

View Full ACIU Social Stream

Latest ACIU News From Around the Web

Below are the latest news stories about AC IMMUNE SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | November 25, 2022

AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and immunogenicity of ACI-35 and JACI-35, developed in collaboration with Janssen PharmaceuticalsCollaboration partner Genentech/Roche to present pharmacodynamic effects of semorinemab on plasma and CSF Tau biomarkers from “Lauriet” Phase 2 trial in mild-to-moderate Alzheimer’s diseaseBanner Alzheimer’

Yahoo | November 23, 2022

AC Immune to Present at the Jefferies London Healthcare Conference

LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies London Healthcare Conference, which is taking place from November 15 – 17, 2022. During the fireside chat, AC Immune’s CEO Dr. Andrea Pfeifer will provide an overview of the

Yahoo | November 8, 2022

AC Immune SA (ACIU) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on AC Immune SA (ACIU - Research Report) today and set a price target of $16.00. The company's shares closed last Friday at $2.90.According to TipRanks, Fein is an analyst with an average return of -10.4% and a 34.00% success rate. Fein covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, ACADIA Pharmaceuticals, and Amarin.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AC Immune SA with a $16.00 average price target.

Jason Carr on TipRanks | October 31, 2022

Shareholders in AC Immune (NASDAQ:ACIU) are in the red if they invested five years ago

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...

Yahoo | October 29, 2022

Read More 'ACIU' Stories Here

ACIU Price Returns

1-mo -12.50%
3-mo -13.40%
6-mo -23.17%
1-year -49.80%
3-year -68.18%
5-year -78.73%
YTD -49.09%
2021 -4.26%
2020 -39.32%
2019 -9.84%
2018 -26.17%
2017 -1.39%

Continue Researching ACIU

Want to see what other sources are saying about AC Immune SA's financials and stock price? Try the links below:

AC Immune SA (ACIU) Stock Price | Nasdaq
AC Immune SA (ACIU) Stock Quote, History and News - Yahoo Finance
AC Immune SA (ACIU) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7817 seconds.